GLP-1 & Incretin Science

The Obesity Drug Pipeline in 2026

UKPWritten and published by UK Peptides3 min readUpdated 5 cited sources

The short answer

The 2026 obesity pipeline splits along two axes: how many receptors a molecule engages, and how it is administered. Retatrutide leads on magnitude as a triple agonist, CagriSema and amycretin add amylin to GLP-1, survodutide and mazdutide add glucagon, and orforglipron is the first non-peptide taken as a tablet.

Key facts

Largest reported reduction
Retatrutide: 28.3% at 80 weeks
First non-peptide approved
Orforglipron: MHRA, 10 Aug 2026
Amylin + GLP-1
CagriSema, amycretin
Glucagon-containing
Retatrutide, survodutide, mazdutide
Approved in China
Mazdutide
Highest oral Phase 2
Aleniglipron: 15.3% at 44 weeks
Common limitation
Gastrointestinal tolerability across all

The two axes that organise the field

Almost every compound in development can be placed by answering two questions. How many receptors does it engage: one, two or three? And is it a peptide, which generally means injection, or a small molecule, which can be a tablet? Adding receptors has consistently increased effect size and consistently increased gastrointestinal burden. The oral trade-off looked equally consistent until 2026: orforglipron reported 11.2% where injectable multi-agonists report twice that. Aleniglipron has complicated it, reporting 15.3% absolute at 44 weeks in Phase 2, still short of retatrutide but no longer in a different league. The gap between routes now looks narrower than the gap between one receptor and three.

Triple agonists: retatrutide

Retatrutide engages GIP, GLP-1 and glucagon receptors from a single 39-residue peptide. TRIUMPH-1 reported mean reduction of 28.3% at 80 weeks on 12 mg, the largest figure yet reported for a single molecule, with a 104-week extension reaching 30.3% in participants with baseline BMI of 35 or above. It remains investigational everywhere; an FDA filing was signalled for Q1 2027.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Amylin combinations: CagriSema and amycretin

Amylin is a separate satiety hormone co-secreted with insulin, and combining amylin agonism with GLP-1 agonism is the other main strategy for increasing effect size. CagriSema is a fixed-dose combination of cagrilintide and semaglutide, both at 2.4 mg once weekly. Amycretin takes the harder route, engaging both GLP-1 and amylin receptors from one molecule, and exists in both weekly subcutaneous and daily oral forms.

Glucagon-containing dual agonists: survodutide and mazdutide

Adding glucagon-receptor activity raises energy expenditure and has a particular effect on hepatic fat, which is why survodutide has been pursued in metabolic liver disease alongside obesity. Mazdutide, a GLP-1/glucagon dual agonist developed by Innovent with Eli Lilly, is approved in China but not in the United States or European Union, and reported roughly 20% reduction on 9 mg in Chinese Phase 3 work.

The oral route: orforglipron

Orforglipron is the outlier because it is not a peptide at all. It reached 11.2% mean reduction at 72 weeks on its highest dose. That is well below the injectable multi-agonists, but it is an ordinary tablet with no absorption enhancer, no fasting window and conventional manufacturing economics. The MHRA authorised it on 10 August 2026, the first such approval in Europe. Aleniglipron, a second oral non-peptide from Structure Therapeutics, has since reported substantially higher Phase 2 figures (15.3% absolute at 44 weeks on 180 mg, with no plateau reached), which suggests orforglipron's effect size reflects that molecule rather than a ceiling on the oral route.

What everything in the pipeline still shares

Gastrointestinal adverse events dominate across every compound and every mechanism, and discontinuation rates rise with dose in all of them. Weight regain after cessation is unresolved across the entire class. Adding receptors has not solved either problem, and neither has changing route.

Quick reference

CompoundReceptorsRouteReported reductionStatus
RetatrutideGIP/GLP-1/glucagonWeekly injection28.3% @ 80 wksInvestigational
CagriSemaAmylin + GLP-1Weekly injection22.7% @ 68 wksFiled / under review
AmycretinGLP-1 + amylinWeekly SC or daily oralUp to 14.5% @ 36 wksEntering Phase 3
MazdutideGLP-1/glucagonWeekly injection~20% (9 mg, Ph3)Approved in China
SurvodutideGLP-1/glucagonWeekly injectionPhase 3 reportedInvestigational
OrforglipronGLP-1 onlyDaily tablet11.2% @ 72 wksAuthorised (UK)
AleniglipronGLP-1 onlyDaily tablet15.3% @ 44 wks (Ph2)Investigational

Frequently asked questions

Which compound produces the largest reduction?

Retatrutide, on the figures reported so far: 28.3% at 80 weeks in TRIUMPH-1. It is also still investigational, so that number comes from trials rather than clinical use.

Why does the tablet lose less weight?

Because orforglipron engages only the GLP-1 receptor. The larger figures come from molecules adding GIP, glucagon or amylin, and no small molecule has yet achieved that. Route matters less than receptor count. Aleniglipron is also an oral single-receptor agonist and reported 15.3% in Phase 2.

Are any of these available in the UK?

Orforglipron is authorised as Foundayo. The rest are investigational or, in mazdutide's case, approved only in China.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.